Rosiglitazone

• 

  Subject Areas on Research

  • Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. 
  • Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). 
  • Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. 
  • Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. 
  • In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. 
  • Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. 
  • Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. 
  • Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone. 
  • Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. 
  • Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. 
  • Results of a reevaluation of cardiovascular outcomes in the RECORD trial. 
  • Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. 
  • Rosiglitazone induces mitochondrial biogenesis in mouse brain. 
  • Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. 
  • Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. 
  • The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. 
  • The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. 
  • The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. 
  • Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. 
  • Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells.